Recent Biotech Funding, Deals and Partnerships
Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.
This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.
Included in the report's coverage are the following data points
This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.
The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.
The following are among the companies covered in this report:
Related Reports:PCR-based Personalized Medicine Tests: White Paper
Apr 22, 2016 - KLI5978232 - $0.00
Biotechnology Companies in Emerging Markets (China, Singapore, Brazil, South Africa, South Korea, Turkey, India, Russia)
Aug 17, 2015 - KLI5668767 - $750.00
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 6th Edition
Apr 30, 2014 - KLI5237347 - $3,995.00
Mass Spectrometry in Clinical Applications (MALDI-TOF, Triple Quad, QTRAP, Ion Trap, GCMS, Orbitrap & Ion-Orbitrap, QTOF, Other Mass Spec)
Apr 29, 2014 - KLI5235894 - $2,995.00
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
May 8, 2013 - KLI5036103 - $2,995.00
Epigenetics: Applications for Pharmaceuticals and Diagnostics (Methylation, Histone Modification and miRNA expression)
Aug 10, 2012 - KLI3860511 - $995.00
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
May 11, 2012 - KLI3889488 - $3,995.00
World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
Mar 1, 2012 - KLI6640829 - $3,500.00
Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer’s, Diabetes, Arthritis and Other Diseases)
Jan 1, 2012 - KLI6490034 - $1,995.00
Outsourcing in Drug Development: The Contract CRO, Clinical Trial Lab and EDC Market
Jan 1, 2012 - KLI6687130 - $1,995.00
Questions?Contact a research specialist >
Live Chat Software
Most Popular ResearchNext Generation Sequencing (NGS) Markets 2015 (Systems, Consumables, Services, Acquisitions, Agreements, Competitive Analysis, Platforms, Applications, Brand Ownership and Other Trends) Proteomics Markets for Clinical IVD Applications and Research Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets) Growth Potential of Specific Biomarker-Based Tests: White Paper Physician Office Laboratory (POL) Markets, 3rd Edition (Markets for Office-Based Chemistry, Glucose, Coagulation PT, Autoimmune, HIV, Hep, Cardiac Markers, PSA, Flu, HbA1c, Hematology, FOB and Other Tests) Mergers and Acquisitions in the IVD Market